198 related articles for article (PubMed ID: 34315393)
1. Recent Achievements about Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents.
Farzipour S; Shaghaghi Z; Abbasi S; Albooyeh H; Alvandi M
Anticancer Agents Med Chem; 2022; 22(8):1496-1510. PubMed ID: 34315393
[TBL] [Abstract][Full Text] [Related]
2. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
Kozempel J; Mokhodoeva O; Vlk M
Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of potential chelating agents for radium.
Henriksen G; Hoff P; Larsen RH
Appl Radiat Isot; 2002 May; 56(5):667-71. PubMed ID: 11993940
[TBL] [Abstract][Full Text] [Related]
4. Targeted and Nontargeted α-Particle Therapies.
McDevitt MR; Sgouros G; Sofou S
Annu Rev Biomed Eng; 2018 Jun; 20():73-93. PubMed ID: 29345977
[TBL] [Abstract][Full Text] [Related]
5. Actinium-225 targeted alpha particle therapy for prostate cancer.
Bidkar AP; Zerefa L; Yadav S; VanBrocklin HF; Flavell RR
Theranostics; 2024; 14(7):2969-2992. PubMed ID: 38773983
[TBL] [Abstract][Full Text] [Related]
6. Targeted alpha therapy: part I.
Elgqvist J
Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy with alpha-particle emitting radionuclides.
Zalutsky MR; Pozzi OR
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
[TBL] [Abstract][Full Text] [Related]
8. TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using
Minnix M; Li L; Yazaki PJ; Miller AD; Chea J; Poku E; Liu A; Wong JYC; Rockne RC; Colcher D; Shively JE
J Nucl Med; 2021 Jan; 62(1):55-61. PubMed ID: 32620701
[TBL] [Abstract][Full Text] [Related]
9. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
Lee D; Li M; Bednarz B; Schultz MK
Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
[TBL] [Abstract][Full Text] [Related]
10. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
Vaidyanathan G; Zalutsky MR
Curr Radiopharm; 2011 Oct; 4(4):283-94. PubMed ID: 22202151
[TBL] [Abstract][Full Text] [Related]
11. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.
Maguire WF; McDevitt MR; Smith-Jones PM; Scheinberg DA
J Nucl Med; 2014 Sep; 55(9):1492-8. PubMed ID: 24982438
[TBL] [Abstract][Full Text] [Related]
12. Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.
Bruchertseifer F; Kellerbauer A; Malmbeck R; Morgenstern A
J Labelled Comp Radiopharm; 2019 Sep; 62(11):794-802. PubMed ID: 31369165
[TBL] [Abstract][Full Text] [Related]
13. Actinium-225 in targeted alpha-particle therapeutic applications.
Scheinberg DA; McDevitt MR
Curr Radiopharm; 2011 Oct; 4(4):306-20. PubMed ID: 22202153
[TBL] [Abstract][Full Text] [Related]
14. Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides.
Henriksen G; Schoultz BW; Michaelsen TE; Bruland ØS; Larsen RH
Nucl Med Biol; 2004 May; 31(4):441-9. PubMed ID: 15093814
[TBL] [Abstract][Full Text] [Related]
15. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.
Miederer M; Scheinberg DA; McDevitt MR
Adv Drug Deliv Rev; 2008 Sep; 60(12):1371-82. PubMed ID: 18514364
[TBL] [Abstract][Full Text] [Related]
16. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
17. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
Huclier-Markai S; Alliot C; Varmenot N; Cutler CS; Barbet J
Curr Top Med Chem; 2012; 12(23):2642-54. PubMed ID: 23339760
[TBL] [Abstract][Full Text] [Related]
18. Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225.
Castillo Seoane D; de Saint-Hubert M; Crabbe M; Struelens L; Koole M
Q J Nucl Med Mol Imaging; 2020 Sep; 64(3):265-277. PubMed ID: 32441067
[TBL] [Abstract][Full Text] [Related]
19. Bismuth chelation for targeted alpha therapy: Current state of the art.
Franchi S; Di Marco V; Tosato M
Nucl Med Biol; 2022; 114-115():168-188. PubMed ID: 35753940
[TBL] [Abstract][Full Text] [Related]
20. Advancements in cancer therapy with alpha-emitters: a review.
Imam SK
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):271-8. PubMed ID: 11516878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
